<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332420</url>
  </required_header>
  <id_info>
    <org_study_id>HQH-201705</org_study_id>
    <nct_id>NCT03332420</nct_id>
  </id_info>
  <brief_title>The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome</brief_title>
  <official_title>A Real-world Study to Evaluate the Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Institute of Pediatrics, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qidong Gaitianli Medicines Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multisite, open-label, prospective and registered study designed to evaluate the
      efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multisite, open-label, prospective and registered study designed to evaluate the
      efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic
      syndrome(PNS). The study will be Planned at 1500 participants, and subjects will be on study
      for up to one year. Data will be collected by authorized physicians for 48 weeks. all of the
      data included demographic characteristics, information about PNS, laboratory tests and
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of positive urine protein test changing to the negative result</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <description>Duration of positive urine protein test changing to the negative result was measured from day 1 until the time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of positive to negative urine protein</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of negative urine protein subjects to the total number of subjects, measured from day 1 until the time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The decrease of 24-hour urine protein level</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>Compared 24-hour urine protein level between baseline and follow-up timepoint, measured from day 1 until time of positive urine protein test changing to negative, assessed up to 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of blood albumin levels</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>Compared blood albumin levels between baseline and follow-up timepoint, assessed up to 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of PNS</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of recurrent subjects to the total number of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of infectious complications of PNS</measure>
    <time_frame>48 Weeks after treatment</time_frame>
    <description>The proportion of complicated infectious subjects to the total number of subjects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Observational 1</arm_group_label>
    <description>Huaiqihuang Granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 2</arm_group_label>
    <description>Standard treatment+Huaiqihuang Granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational 3</arm_group_label>
    <description>Standard treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children are diagnosed with primary nephrotic syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In accordance with Pediatric Branch , the Chinese Medical Association in 2009:
             guidelines for diagnosis and treatment of common kidney diseases in children (for
             trial)Ⅰ. Hormone-sensitive, relapsed/dependent nephrotic syndrome diagnostic and
             evidence-based guidelines; Ⅲ.Diagnostic criteria for the diagnostic and evidence-based
             guidelines for hormone-resistant nephrotic syndrome, which means children who are
             diagnosed with primary nephrotic syndrome should be included;

          2. Age from 1 to18;

          3. ALT and AST levels do not exceed twice the upper limit of the normal range;;

          4. Provision of written informed consent by legal guardians.

        Exclusion Criteria:

          1. a variety of secondary nephrotic syndromes are caused by infectious diseases such as
             lupus nephritis, hepatitis b associated nephritis, purpura nephritis, and EB virus,
             cytomegalovirus (CMV), etc;

          2. with combined diseases of cardiovascular, liver, hematopoietic system, mental
             disorders and other serious diseases;

          3. History of diabetes or examinations showed elevated blood glucose levels;

          4. Participation in other ongoing clinical trials or during their observation period
             within the last three months prior to visit 1;

          5. Previous/concomitant treatment with any other immunomodulators within the last three
             months prior to visit 1 ;

          6. Patients who are unlikely to adhere to the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaoying Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children’s Hospital of The Capital Institute of Pediatrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonghui Lu, Ph.D</last_name>
    <phone>+0086-13801462500</phone>
    <email>lyh307@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chaoying Chen, Professor</last_name>
    <phone>+0086-13911993856</phone>
    <email>chenchaoying484@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Capital Institute Of Pediatrics</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaoying Chen, Professor</last_name>
      <phone>+0086-13911993856</phone>
      <email>chenchaoying484@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huaiqihuang granule</keyword>
  <keyword>primary nephrotic syndrome</keyword>
  <keyword>multisite</keyword>
  <keyword>prospective</keyword>
  <keyword>open-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

